MissionIR Articles

International Stem Cell Corp., a clinical stage biotech company developing novel stem cell-based therapies, has signed a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health to conduct phase I/IIa clinical…

Parkinson’s disease is a progressive movement disorder, meaning that symptoms continue to get worse over time. Approximately one million people in the US are living with this disease. While there is currently no cure and…

Currently available Parkinson’s disease treatments, while capable of improving the early symptoms of the disease, lose their effect as the disease progresses and produce involuntary writing movements in the patients. As of yet there is…

International Stem Cell Corp. is tackling some of the world’s most debilitating health maladies with a powerful new stem cell technology that employs parthenogenesis. Parthenogenesis is a type of reproduction that takes place in the…

International Stem Cell Corporation (OTC: ISCO) focuses on utilizing patented human parthenogenetic stem cells (hPSC), developed from unfertilized embryos, to treat Parkinson’s, retinal, and liver diseases where replacing dead and dying cells with new ones…

The true forefront in medicine today is a broad offensive where medical and research professionals are now pulling out all the stops in a never-ending war against broad-spectrum degenerative diseases like cancer or degenerative diseases…

International Stem Cell Corp. this morning posted a business update along with operating results for the three- and nine-month periods ended September 30, 2105. Among other results, the California-based biotech company reported an increase in…

The ethical controversy surrounding stem cell research does not reach the International Stem Cell Corp. as it employs non-embryonic cells (unfertilized) for exploring and attempting to treat different diseases. The company has developed the first…

California-based International Stem Cell Corporation this morning announced that its wholly owned subsidiary, Cyto Therapeutics, has signed a Letter of Intent (LOI) with Royal Melbourne Hospital in Australia to conduct phase I/IIa clinical trials of…

A leader in regenerative medicine, International Stem Cell Corp. uses its parthenogenesis stem cell technology to address immune rejection and self-renewing cells. This technology uses unfertilized eggs that have cells with a duplicate set of…

International Stem Cell Corp. continues its pursuit of advancing regenerative medicine through its use and research of stem cells in the white hot biotechnology space. ISCO uses parthenogenesis, a stem cell technology that makes use…

International Stem Cell Corp., a California-based biotech company developing novel stem cell-based therapies and biomedical products, this morning said it will make an oral presentation on the comprehensive results of its preclinical development of human…

The International Stem Cell Corporation, a biotechnology company, continues its developmental research of using stem cells to advance regenerative medicine. The company uses stem cell technology called parthenogenesis that uses unfertilized eggs to address immune…

International Stem Cell Corp., a biotechnology company developing novel stem cell-based therapies, announced that its scientific team has developed a robust innovative technology to generate functional articular cartilage from the patient’s own skin or adipose…

Stem cell technology’s real untilled and still extremely fertile soil is the therapeutics market, where injected cells could help repair damaged tissue systems and thus effectively treat many conditions, including degenerative ones, for which the…

Today before the opening bell, International Stem Cell Corp. announced that Mahnaz Ebrahimi will be taking over as the new chief financial officer, effective September 14, 2015. The prior CFO, Jay Novak, ended his employment…

The promise of stem cell tissue transplantation is particularly exciting for conditions such as Parkinson’s disease, an incurable and progressive disorder of the nervous system characterized by a gradual at first, and then increasingly severe…

Today before the opening bell, International Stem Cell Corp. announced that it has entered into the second phase of the existing Research Agreement with Rohto Pharmaceutical Co., Ltd. (“Rohto”), a global Japanese pharmaceutical company recognized…

International Stem Cell (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, this morning announced that company board member and Chief Scientific Officer Ruslan Semechkin, PhD, will present at the…

On the cusp of milestone TGA (Therapeutic Goods Administration) authorization in Australia to start clinical trials in its breakthrough Parkinson’s disease (PD) treatment using human parthenogenetic neural stem cells (hpNSCs), International Stem Cell Corp. (OTCQB:…